Why Faeth Therapeutics, Inc.’s (FTH) Stock Is Down 5.73%

By Tudor Pop
November 19, 2026
Featured Tickers:
FTH

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Faeth Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Faeth Therapeutics, Inc.’s stock price such as:

  • Faeth Therapeutics, Inc.’s current stock price and volume
  • Why Faeth Therapeutics, Inc.’s stock price changed recently
  • Upgrades and downgrades for FTH from analysts
  • FTH’s stock price momentum as measured by its relative strength

About Faeth Therapeutics, Inc. (FTH)

Before we jump into Faeth Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company’s pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.

Want to learn more about Faeth Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Faeth Therapeutics, Inc..

Learn More About A+ Investor

Faeth Therapeutics, Inc.’s Stock Price as of Market Close

As of November 19, 2026, 11:30 AM, CST, Faeth Therapeutics, Inc.’s stock price was $8.760.

Faeth Therapeutics, Inc. is up 0.46% from its previous closing price of $8.720.

During the last market session, Faeth Therapeutics, Inc.’s stock traded between $8.580 and $9.000. Currently, there are approximately 25.84 million shares outstanding for Faeth Therapeutics, Inc..

Faeth Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Faeth Therapeutics, Inc. Stock Price History

Faeth Therapeutics, Inc.’s (FTH) price is currently down 53.13% so far this month.

During the month of November, Faeth Therapeutics, Inc.’s stock price has reached a high of $22.050 and a low of $8.580.

Over the last year, Faeth Therapeutics, Inc. has hit prices as high as $42.143 and as low as $7.450.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Faeth Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 18, 2026, there was 1 analyst who downgraded Faeth Therapeutics, Inc.’s stock and 3 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Faeth Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Faeth Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Faeth Therapeutics, Inc. (FTH) by visiting AAII Stock Evaluator.

Relative Price Strength of Faeth Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 18, 2026, Faeth Therapeutics, Inc. has a weighted four-quarter relative price strength of 31.68%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Faeth Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Faeth Therapeutics, Inc. Stock Price: Bottom Line

As of November 19, 2026, Faeth Therapeutics, Inc.’s stock price is $8.760, which is up 0.46% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Faeth Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Learn More About A+ Investor

Find New Stock Opportunities With Included With AAII Platinum
O'Neil CAN SLIM Screen: 38.3% Compared to S&P 500
at only 23.3%

Since Inception. Data as of 12/31/2024.




Try AAII Platinum and get full access to
769.3% Stock Superstars Portfolio Total Return Since Inception
Compare to:
710.3% iShare DOW Jones
U.S. Index ETF (IYY)

SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.

Get your free copy of our special report analyzing the tech stocks most likely to outperform the market.

Download the FREE Report Here:

BECOME A MEMBER FOR ONLY $2

Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.